Park Medi World IPO: The good and the bad

Summary: Park Medi World, the second-largest private hospitality chain in North India, is set to go public on December 10, 2025. Let’s analyse its positives, negatives and financials to help you better decide whether its IPO is worth subscribing to.

Park Medi World, a private hospital chain in North India, will open its IPO (initial public offering) on December 10, 2025 and close on December 12, 2025. Of its total issue size of Rs 920 crore, Rs 770 crore will be raised through a fresh issue, while the remaining Rs 150 crore will be an offer for sale (OFS).

We break down the company’s strengths, weaknesses, past financial performance and valuations to help you make an informed investment decision.

What the company does

Park Medi World is the second-largest private hospital chain in North India, with 3,000 beds, and the largest in Haryana with 1,600 beds. It operates 14 NABH-accredited multi-super specialty hospitals, eight of which also carry NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation, spread across Haryana, Delhi, Punjab and Rajasthan.

The group offers more than 30 specialties, supported by over 1,000 doctors and 2,100 nurses. Founded by Dr Ajit Gupta in 2005, the network has grown through a mix of greenfield expansion and strategic acquisitions across North India.

Track record and valuation

Between FY23 and FY25, Park Medi World’s revenue grew at a modest 5.4 per cent annually, while both EBIT (earnings before interest and tax) and PAT (profit after tax) reported negative growth. Such numbers suggest that the company’s financial footing has been shaky throughout the three-year period.

At the upper end of the price band (Rs 162), Park Medi World’s stock is expected to be valued at over 29 times its TTM earnings and 3.6 times its book value. In comparison, Park Medi World’s peers trade at a P/E and P/B of 58.6 times and 8.7 times, respectively.

The good

Here are some of Park Medi World’s positives.

#1 Among the leading private hospital chains in North India

Park Medi World is the second-largest private hospital chain in North India, and the largest in Haryana, with 3,250 beds as of September 2025. Its long-standing presence in the region has helped it understand local preferences and expand both organically and through acquisitions.

The company follows a cluster-based strategy, building hospitals in adjoining areas to share resources, strengthen its brand and improve operating efficiency. Its network now spans 14 NABH-accredited multi-super specialty hospitals across Delhi, Haryana, Rajasthan and Punjab, equipped with modern facilities, 870 ICU beds, 67 operation theatres and two cancer units. Several hospitals have also been approved for kidney transplants, underscoring the group’s capability in complex and specialised care.

#2 Growing footprint through acquisitions

Park Medi World has expanded its footprint largely through acquisitions, adding 1,650 beds by integrating eight hospitals across North India. These deals have broadened its regional presence and supported growth in capacity, revenue and profitability. The company is now pursuing another acquisition through its subsidiary, Blue Heavens, which has received NCLT approval to take over Durha Vitrak (Febris Multi Specialty Hospital) in Delhi. As part of the resolution plan, Blue Heavens will settle creditor dues and infuse fresh equity, after which Durha Vitrak will become its wholly owned subsidiary.

The bad

Below are some of Park Medi World’s weaknesses.

#1 Revenue concentrated in a single region

A large share of Park Medi World’s revenue comes from its hospitals in Haryana, which contributed between 69 per cent and 84 per cent over FY23 to FY25 and the first half of FY25. This heavy reliance on a single state increases concentration risk, as any disruption to these hospitals or adverse developments in Haryana could materially affect the company’s operations and financial performance.

#2 Dependence on a handful of specialties

Most of Park Medi World’s revenue comes from a handful of key specialties, such as internal medicine, neurology, urology, gastroenterology, cardiology, general surgery and orthopaedics, which together account for 86 to 93 per cent of its operating income across FY23 to FY25 and the first half of FY25. This dependence on a narrow set of specialties heightens concentration risk, and any slowdown or adverse development in these areas could hurt the company’s performance.

#3 Inconsistent bed occupancy rates

Park Medi World relies heavily on revenue from its in-patient department, making occupancy levels a key driver of performance. Its bed occupancy dropped from 75.13 per cent in FY23 to 59.81 per cent in FY24, before inching up to 61.63 per cent in FY25. Sustained weakness in occupancy could limit returns on capital invested, pressure operating efficiency and weigh on profitability.

Where will the IPO proceeds go?

Here is how Park Medi World plans to utilise its fresh issue of Rs 770 crore:

• Around Rs 380 crore will be used for paying off the company’s debts
• Around Rs 60.5 crore will be allocated for the development of a new hospital and expansion of an existing hospital by the company’s subsidiary, Park Medicity
• Rs 27.5 crore will be directed towards the purchase of new medical equipment

The remaining funds will be utilised for inorganic acquisitions and general corporate purposes.

So, should you subscribe to the Park Medi World IPO?

At Value Research, we urge investors to be careful with IPOs. Many listings lose steam after the initial buzz, often disappointing those who jump in with the aim of making quick gains. And for anyone focused on building long-term wealth, IPOs are rarely the ideal entry point.

The real compounding stories lie elsewhere: in businesses that have weathered multiple market cycles and delivered consistently over time. That’s where Value Research Stock Advisor comes in. We help you identify companies with solid fundamentals, dependable performance and the resilience to keep compounding well beyond their IPO moment.

Subscribe to Stock Advisor today

Also read: Wakefit Innovations IPO: Should you subscribe?